BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 15967103)

  • 1. A specific inhibitor of TGF-beta receptor kinase, SB-431542, as a potent antitumor agent for human cancers.
    Halder SK; Beauchamp RD; Datta PK
    Neoplasia; 2005 May; 7(5):509-21. PubMed ID: 15967103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility.
    Hjelmeland MD; Hjelmeland AB; Sathornsumetee S; Reese ED; Herbstreith MH; Laping NJ; Friedman HS; Bigner DD; Wang XF; Rich JN
    Mol Cancer Ther; 2004 Jun; 3(6):737-45. PubMed ID: 15210860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7.
    Inman GJ; Nicolás FJ; Callahan JF; Harling JD; Gaster LM; Reith AD; Laping NJ; Hill CS
    Mol Pharmacol; 2002 Jul; 62(1):65-74. PubMed ID: 12065756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542.
    Laping NJ; Grygielko E; Mathur A; Butter S; Bomberger J; Tweed C; Martin W; Fornwald J; Lehr R; Harling J; Gaster L; Callahan JF; Olson BA
    Mol Pharmacol; 2002 Jul; 62(1):58-64. PubMed ID: 12065755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7.
    DaCosta Byfield S; Major C; Laping NJ; Roberts AB
    Mol Pharmacol; 2004 Mar; 65(3):744-52. PubMed ID: 14978253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SB-431542 and Gleevec inhibit transforming growth factor-beta-induced proliferation of human osteosarcoma cells.
    Matsuyama S; Iwadate M; Kondo M; Saitoh M; Hanyu A; Shimizu K; Aburatani H; Mishima HK; Imamura T; Miyazono K; Miyazawa K
    Cancer Res; 2003 Nov; 63(22):7791-8. PubMed ID: 14633705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo.
    Uhl M; Aulwurm S; Wischhusen J; Weiler M; Ma JY; Almirez R; Mangadu R; Liu YW; Platten M; Herrlinger U; Murphy A; Wong DH; Wick W; Higgins LS; Weller M
    Cancer Res; 2004 Nov; 64(21):7954-61. PubMed ID: 15520202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The ALK-5 inhibitor A-83-01 inhibits Smad signaling and epithelial-to-mesenchymal transition by transforming growth factor-beta.
    Tojo M; Hamashima Y; Hanyu A; Kajimoto T; Saitoh M; Miyazono K; Node M; Imamura T
    Cancer Sci; 2005 Nov; 96(11):791-800. PubMed ID: 16271073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of transforming growth factor-β via the activin receptor-like kinase-5 inhibitor attenuates pulmonary fibrosis.
    Koh RY; Lim CL; Uhal BD; Abdullah M; Vidyadaran S; Ho CC; Seow HF
    Mol Med Rep; 2015 May; 11(5):3808-13. PubMed ID: 25585520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vasohibin-1 expression is regulated by transforming growth factor-β/bone morphogenic protein signaling pathway between tumor-associated macrophages and pancreatic cancer cells.
    Shen Z; Seppänen H; Kauttu T; Vainionpää S; Ye Y; Wang S; Mustonen H; Puolakkainen P
    J Interferon Cytokine Res; 2013 Aug; 33(8):428-33. PubMed ID: 23651239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective inhibition of activin receptor-like kinase 5 signaling blocks profibrotic transforming growth factor beta responses in skin fibroblasts.
    Mori Y; Ishida W; Bhattacharyya S; Li Y; Platanias LC; Varga J
    Arthritis Rheum; 2004 Dec; 50(12):4008-21. PubMed ID: 15593186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pyridoxine 5'-phosphate oxidase is a novel therapeutic target and regulated by the TGF-β signalling pathway in epithelial ovarian cancer.
    Zhang L; Zhou D; Guan W; Ren W; Sun W; Shi J; Lin Q; Zhang J; Qiao T; Ye Y; Wu Y; Zhang Y; Zuo X; Connor KL; Xu G
    Cell Death Dis; 2017 Dec; 8(12):3214. PubMed ID: 29238081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct roles of transforming growth factor-β signaling and transforming growth factor-β receptor inhibitor SB431542 in the regulation of p21 expression.
    Koo BH; Kim Y; Je Cho Y; Kim DS
    Eur J Pharmacol; 2015 Oct; 764():413-423. PubMed ID: 26187313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ki26894, a novel transforming growth factor-beta type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line.
    Ehata S; Hanyu A; Fujime M; Katsuno Y; Fukunaga E; Goto K; Ishikawa Y; Nomura K; Yokoo H; Shimizu T; Ogata E; Miyazono K; Shimizu K; Imamura T
    Cancer Sci; 2007 Jan; 98(1):127-33. PubMed ID: 17129361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of high glucose and TGF-beta1 on the expression of collagen IV and vascular endothelial growth factor in mouse podocytes.
    Iglesias-de la Cruz MC; Ziyadeh FN; Isono M; Kouahou M; Han DC; Kalluri R; Mundel P; Chen S
    Kidney Int; 2002 Sep; 62(3):901-13. PubMed ID: 12164872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1.
    Subramanian G; Schwarz RE; Higgins L; McEnroe G; Chakravarty S; Dugar S; Reiss M
    Cancer Res; 2004 Aug; 64(15):5200-11. PubMed ID: 15289325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential Proteome Analysis Identifies TGF-β-Related Pro-Metastatic Proteins in a 4T1 Murine Breast Cancer Model.
    Sato M; Matsubara T; Adachi J; Hashimoto Y; Fukamizu K; Kishida M; Yang YA; Wakefield LM; Tomonaga T
    PLoS One; 2015; 10(5):e0126483. PubMed ID: 25993439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The anticancer agent prodigiosin induces p21WAF1/CIP1 expression via transforming growth factor-beta receptor pathway.
    Soto-Cerrato V; Viñals F; Lambert JR; Pérez-Tomás R
    Biochem Pharmacol; 2007 Nov; 74(9):1340-9. PubMed ID: 17765876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of growth and metastasis of mouse mammary carcinoma by selective inhibitor of transforming growth factor-beta type I receptor kinase in vivo.
    Ge R; Rajeev V; Ray P; Lattime E; Rittling S; Medicherla S; Protter A; Murphy A; Chakravarty J; Dugar S; Schreiner G; Barnard N; Reiss M
    Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4315-30. PubMed ID: 16857807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EW-7203, a novel small molecule inhibitor of transforming growth factor-β (TGF-β) type I receptor/activin receptor-like kinase-5, blocks TGF-β1-mediated epithelial-to-mesenchymal transition in mammary epithelial cells.
    Park CY; Kim DK; Sheen YY
    Cancer Sci; 2011 Oct; 102(10):1889-96. PubMed ID: 21707864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.